MYPS:NASDAQPLAYSTUDIOS, Inc. Analysis
Data as of 2026-05-24 - not real-time
$0.47
Latest Price
8/10Risk
Risk Level: High
Executive Summary
PLAYSTUDIOS, Inc. (MYPS) is trading near its 30‑day support of $0.402 with a current price of $0.4725, while the 20‑day SMA (0.446) sits below the 50‑day SMA (0.457) and both are well under the 200‑day SMA (0.685), indicating a lingering bearish momentum. The RSI of 53 suggests the stock is neither oversold nor overbought, and the MACD histogram shows a modest bullish signal despite the overall downtrend. Volume has been increasing, which could signal renewed buying interest, but the 30‑day volatility of ~86% and a beta of 0.71 underscore a high‑risk price profile. Recent news disclosed the company’s first‑quarter results, highlighting continued revenue decline of 7 % year‑over‑year and negative operating margins, yet the firm reported solid operating cash flow of $26.8 M and a healthy cash balance of $103.7 M.
Fundamentally, MYPS trades at a forward PE of 36.5 versus an industry average of 17, but its price‑to‑book and price‑to‑sales ratios are both below 0.3, reflecting deep discounting. The DCF‑derived fair value of approximately $3.60 implies a potential upside of over 200 % from current levels. Despite negative earnings and a modest ROE, the company’s gross margin exceeds 75 % and its loyalty platform offers a strategic growth avenue. Given the extreme greed sentiment in the market, the stock appears attractively undervalued but remains highly speculative due to earnings volatility and sector exposure.
Fundamentally, MYPS trades at a forward PE of 36.5 versus an industry average of 17, but its price‑to‑book and price‑to‑sales ratios are both below 0.3, reflecting deep discounting. The DCF‑derived fair value of approximately $3.60 implies a potential upside of over 200 % from current levels. Despite negative earnings and a modest ROE, the company’s gross margin exceeds 75 % and its loyalty platform offers a strategic growth avenue. Given the extreme greed sentiment in the market, the stock appears attractively undervalued but remains highly speculative due to earnings volatility and sector exposure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish SMA alignment and downtrend
- Price hovering above immediate support
- Elevated short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF upside exceeding 200 %
- Strong cash position and positive operating cash flow
- Increasing trading volume indicating renewed interest
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Deep discount to fair value
- High gross margins and loyalty platform growth potential
- Low beta and defensive cash balance
Key Metrics & Analysis
Financial Health
Revenue Growth-6.90%
Profit Margin-15.79%
P/E Ratio36.5
ROE-15.72%
ROA-5.80%
Debt/Equity3.15
P/B Ratio0.3
Op. Cash Flow$26.8M
Free Cash Flow$28.1M
Industry P/E17.0
Technical Analysis
TrendBearish
RSI53.4
Support$0.40
Resistance$0.54
MA 20$0.45
MA 50$0.46
MA 200$0.68
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$3.60
Target Price$1.50
Upside/Downside217.46%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.71
Volatility85.78%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.